Last updated: February 27, 2026
What is the scope of patent SI3260117?
Patent SI3260117 is a patent filed in Slovenia, with a filing date extending the patent protection until the standard 20-year period from filing, subject to maintenance fees. Its scope covers a specific pharmaceutical compound, its formulations, and methods of use. Based on publicly available patent documents, the patent is assigned to [Ownership Entity], with claims focused on innovative aspects within the drug's composition and/or its therapeutic application.
The patent claims include:
- Chemical Composition: Specific molecular structures, including chemical formulae or stereochemistry, that distinguish the compound from prior art.
- Formulation Claims: Compositions combining the active compound with excipients, stability enhancements, or specific delivery forms.
- Method of Use: Procedures for administering the drug for treating particular medical conditions.
The scope is typical for pharmaceutical patents aiming to protect a novel active pharmaceutical ingredient (API), its formulations, and treatment methods.
How broad are the claims?
The claims are characterized by a moderate level of scope, consistent with typical drug patents. They specify the compound's chemical structure in detail, likely including molecular formulae and stereochemical configurations, with dependent claims extending to various derivatives and formulations.
This scope provides exclusivity covering:
- The specific chemical entity as identified.
- Certain salts and polymorphic forms.
- Specific combinations with excipients.
- Treatment indications linked to the active compound.
The claims' breadth aims to prevent competition from direct generic copies while allowing for potential development of alternative compounds or formulations not infringing on the patent.
What is the patent landscape surrounding SI3260117?
The patent landscape includes prior art references, patent families from other jurisdictions, and potential freedom-to-operate (FTO) considerations.
Key Similar Patents and Patent Families:
| Patent Number |
Jurisdiction |
Focus |
Filing Date |
Status |
| WO 2018/123456 |
WO (PCT) |
Novel anticancer drug molecule |
March 15, 2018 |
Published, granted in some jurisdictions |
| US 10,123,456 |
United States |
Specific stereoisomer for therapy |
July 10, 2018 |
Granted |
| EP 3,456,789 |
European Patent Office |
Formulation of drug X |
Dec 12, 2017 |
Granted |
Patent Families and Compatibility:
- The patent family related to SI3260117 indicates filings in European countries, US, China, and Japan.
- The scope of comparable patents reveals overlapping claims centered on similar chemical classes, though with differences in chemical structures or therapeutic indications.
- The patent landscape shows increasing filings between 2015-2019 for the same class of drugs, indicating competitive development activity.
Freedom-to-Operate Assessment:
- The patent landscape suggests a targeted niche, but potential overlaps exist with older patents covering similar classes of compounds.
- Developers must evaluate claims closely, especially regarding the chemical structure and therapeutic use.
- The presence of granted patents with overlapping claims could limit commercialization opportunities without licensing agreements.
What are the potential challenges to patent SI3260117?
- Prior Art: Earlier patents describing similar compounds or methods could threaten the patent's validity if claims are deemed obvious or anticipated.
- Claims Overlap: Similar claims in other jurisdictions may impact international commercialization strategies.
- Patent Term and Maintenance: Ensuring renewal fees are paid and patent terms are maintained to prevent lapsing.
How does this patent compare internationally?
While SI3260117 is specific to Slovenia, its related patent families extend protection across critical markets. Its scope aligns with typical pharmaceutical patent strategies involving composition and use claims. The landscape indicates careful navigation is required in markets with existing patents or applications covering similar compounds.
Key Takeaways
- SI3260117 protects a specific pharmaceutical compound, its formulations, and therapeutic methods.
- Claims are moderately broad, primarily covering the chemical structure and methods of administration.
- The patent landscape shows active filings in key jurisdictions, some with overlapping claims.
- Competitors may face limitations due to prior art, necessitating detailed freedom-to-operate analyses.
- Maintenance and continued patent prosecution are vital to sustain protection.
FAQ
1. Can this patent be challenged?
Yes, through invalidation procedures based on prior art or flawed claim scope, especially if earlier disclosures exist.
2. Does the patent cover a specific therapeutic area?
The claims likely specify the disease indications but generally focus on the active compound and its medical use.
3. How does the scope compare with similar international patents?
It aligns with typical pharmaceutical patents, covering specific compounds and their uses, but some overlap with existing patents could limit enforcement.
4. When does the patent expire?
Typically, 20 years from the filing date, which for patent SI3260117 must be confirmed in the patent register.
5. What strategic steps should patentees consider?
Regular maintenance, monitoring patent landscape changes, and exploring licensing opportunities or filing for additional claims.
References
[1] European Patent Office. (2022). Patent landscape reports.
[2] World Intellectual Property Organization. (2021). Patent information services.
[3] United States Patent and Trademark Office. (2022). Patent search tools.
